ReviewJournal of endocrinological investigation2026
Therapeutic potential of adipose-derived stem cells for noncommunicable diseases.
Review in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell-Penetrating Peptide-Mediated Modulation of Endoplasmic Reticulum Stress: A Bioengineered and Translational Approach.ACS pharmacology & translational science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThe progressive increase in life expectancy has been accompanied by a growing burden of chronic degenerative noncommunicable diseases (NCDs), with major consequences for quality of life and healthcare systems. This scenario underscores the need for innovative therapeutic strategies aimed at preserving organ function and metabolic homeostasis. Adipose-derived stem/stromal cells (ASCs) have emerged as a promising tool in regenerative medicine due to their multipotency, immunomodulatory properties, and paracrine activity.
methodsWe reviewed available preclinical and clinical evidence supporting the therapeutic potential of ASCs in chronic noncommunicable diseases. The analysis focused on ASC biology, mechanisms of action, and current clinical applications, with particular attention to metabolic and endocrine disorders, while also considering cardiovascular, musculoskeletal, neurodegenerative, and other chronic degenerative conditions.
resultsPreclinical and clinical studies indicate that ASCs may contribute to tissue repair and functional recovery through differentiation capacity and paracrine signaling, including anti-inflammatory, angiogenic, and cytoprotective effects. In metabolic and endocrine diseases, ASCs have shown potential to improve insulin sensitivity, support pancreatic function, and mitigate chronic metabolic complications. Additional therapeutic applications have been explored in osteoarthritis, cardiovascular disease, neurodegenerative disorders, chronic intestinal and liver diseases, and age-related tissue degeneration, although the strength of clinical evidence varies across indications.
conclusionsASCs represent a promising regenerative strategy for chronic degenerative NCDs, particularly in the metabolic and endocrine setting. However, clinical translation remains limited by heterogeneous evidence, regulatory challenges, and the need for standardized protocols and well-designed clinical trials.
Indexed as
Identifiers
41484409What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.